MDA Space Ltd. Common Shares (MDA)
Live price chart, market sentiment, and community perspectives for MDA Space Ltd. Common Shares (NYSE: MDA).
Live price chart, market sentiment, and community perspectives for MDA Space Ltd. Common Shares (NYSE: MDA).
Looking at MDA's Q2 2026 numbers, the top-line growth is undeniable with revenues hitting $499 million, up 34% year-over-year. The backlog expanding to $4.0 billion gives us phenomenal forward visibility. However, as a hedge fund PM, I am closely watching the cash flow burn—free cash flow dropped to $(150) million in the quarter. Management is playing an aggressive growth game, but the market will need to digest the dilution from the 23-million-share bought deal priced at US$35.60.
On our trading desk, the liquidity profile looks secure with total liquidity sitting at $1.1 billion and a net cash position of $153 million at quarter-end. The capital raise successfully closed on July 14, 2026, clearing the path for their €567 million cash acquisition of a majority interest in Collecte Localisation Satellites (CLS). Watch for short-term volatility as the market evaluates integration risks versus the sheer scale of this European footprint expansion.
From a technical underwriting perspective, the syndicate led by BMO, RBC, J.P. Morgan, Scotiabank, and BofA executed a textbook upsized bought deal. When evaluating operational health, note that Adjusted EBITDA grew 26% YoY to $96 million with a healthy margin of 19.3%. Candidates and analysts need to emphasize that top-line acceleration is translating into adjusted profitability, even if operating cash flow was temporarily compressed at $(93) million.
When building financial models for MDA Space, analysts must separate GAAP figures from Adjusted metrics carefully. Adjusted net income reached $52 million in Q2, up 13% YoY. Ensure your valuation models account for the expanded share count post-offering, as the 23 million newly issued common shares materially alter per-share metrics for the remainder of 2026.
Market sentiment on MDA remains fundamentally constructive due to raised full-year 2026 guidance. By increasing the midpoint for revenue and adjusted EBITDA expectations following strong Q1 and Q2 reports, leadership is signaling high confidence. Sentiment could sour quickly, though, if free cash flow does not inflect positively in the back half of the fiscal year following heavy deployment into the CLS transaction.
Explore plasma cleansing, somatic organ swaps, and BCI.